BR112014000290A2 - formulações de combinação de darunavir - Google Patents

formulações de combinação de darunavir

Info

Publication number
BR112014000290A2
BR112014000290A2 BR112014000290A BR112014000290A BR112014000290A2 BR 112014000290 A2 BR112014000290 A2 BR 112014000290A2 BR 112014000290 A BR112014000290 A BR 112014000290A BR 112014000290 A BR112014000290 A BR 112014000290A BR 112014000290 A2 BR112014000290 A2 BR 112014000290A2
Authority
BR
Brazil
Prior art keywords
darunavir
combination formulations
formulations
solvate
hiv
Prior art date
Application number
BR112014000290A
Other languages
English (en)
Other versions
BR112014000290B1 (pt
Inventor
Maria Jozef Jans Eugeen
Van Der Avoort Geert
Erna H Heyns Philip
Jos M Mertens Roel
Alfons C Delaet Urbain
Original Assignee
Gilead Sciences Inc
Janssen R&D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Janssen R&D Ireland filed Critical Gilead Sciences Inc
Publication of BR112014000290A2 publication Critical patent/BR112014000290A2/pt
Publication of BR112014000290B1 publication Critical patent/BR112014000290B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Abstract

resumo patente de invenção: "formulações de combinação de darunavir". esta invenção refere-se a formas de dosagem oral sólidas do inibidor do hiv darunavir e/ou um seu sal ou solvato farmaceuticamente aceitável, e a suas formulações de combinação.
BR112014000290-8A 2011-07-07 2012-07-06 Forma de dosagem oral de combinação de darunavir, processo para preparação de uma forma de dosagem oral e uso de granulado de darunavir BR112014000290B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11173067 2011-07-07
EP11173067.7 2011-07-07
PCT/EP2012/063249 WO2013004818A1 (en) 2011-07-07 2012-07-06 Darunavir combination formulations

Publications (2)

Publication Number Publication Date
BR112014000290A2 true BR112014000290A2 (pt) 2017-02-07
BR112014000290B1 BR112014000290B1 (pt) 2022-05-10

Family

ID=46551505

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014000290-8A BR112014000290B1 (pt) 2011-07-07 2012-07-06 Forma de dosagem oral de combinação de darunavir, processo para preparação de uma forma de dosagem oral e uso de granulado de darunavir

Country Status (23)

Country Link
US (3) US20140142070A1 (pt)
EP (1) EP2729130B1 (pt)
JP (1) JP6122427B2 (pt)
KR (1) KR102058097B1 (pt)
CN (1) CN103826616B (pt)
AU (1) AU2012280198B2 (pt)
BR (1) BR112014000290B1 (pt)
CA (1) CA2838659C (pt)
CY (1) CY1121999T1 (pt)
DK (1) DK2729130T3 (pt)
EA (1) EA026587B1 (pt)
ES (1) ES2651212T3 (pt)
HR (1) HRP20171889T1 (pt)
HU (1) HUE035241T2 (pt)
IL (1) IL229933A (pt)
LT (1) LT2729130T (pt)
MX (1) MX343689B (pt)
NO (1) NO2729130T3 (pt)
PL (1) PL2729130T3 (pt)
PT (1) PT2729130T (pt)
RS (1) RS56667B1 (pt)
SI (1) SI2729130T1 (pt)
WO (1) WO2013004818A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035241T2 (en) 2011-07-07 2018-05-02 Janssen Sciences Ireland Uc Darunavir combination products
WO2013130766A1 (en) * 2012-03-01 2013-09-06 Gilead Sciences, Inc. Spray dried formulations
CA3012242C (en) 2012-12-21 2021-11-02 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP3632415A1 (en) 2015-11-09 2020-04-08 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
US20190175509A1 (en) * 2016-08-08 2019-06-13 Hetero Labs Limited High Drug Loaded Tablet Composition for Treating HIV
EP3496719B1 (en) * 2016-08-08 2023-06-14 Hetero Labs Limited A multi-class anti-retroviral composition
WO2018029561A1 (en) 2016-08-08 2018-02-15 Hetero Labs Limited Anti-retroviral compositions
US20180085387A1 (en) * 2016-09-27 2018-03-29 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
US10786518B2 (en) * 2017-07-20 2020-09-29 Janssen Sciences Ireland Uc Compositions and methods of treating HIV
US20200101093A1 (en) 2018-09-28 2020-04-02 Janssen Sciences Ireland Unlimited Company Methods of Treating and Preventing Neuropsychiatric and/or Neurocognitive Complications in Patients Infected with HIV
WO2021180963A1 (en) 2020-03-13 2021-09-16 Janssen Sciences Ireland Unlimited Company A protease inhibitor regimen for treating subjects infected with hiv

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
ES2127938T3 (es) 1993-08-24 1999-05-01 Searle & Co Hidroxietilamino sulfonamidas utiles como inhibidores de proteasas retroviricas.
AU771780B2 (en) 1998-06-23 2004-04-01 Board Of Trustees Of The University Of Illinois, The Fitness assay and associated methods
TWI286476B (en) 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
HUE034389T2 (en) 2002-05-16 2018-02-28 Janssen Sciences Ireland Uc Pseudopolymorphic forms of an HIV protease inhibitor
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2007143422A2 (en) 2006-05-30 2007-12-13 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
TWI411613B (zh) 2006-07-07 2013-10-11 Gilead Sciences Inc 用於改善被細胞色素p450單氧合酶所代謝之治療劑的藥物動力性質之調節劑
MX2009004439A (es) * 2006-10-25 2009-05-11 Mcneil Ppc Inc Composicion de ibuprofeno.
MX2009008935A (es) 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
US20100190809A1 (en) 2007-06-25 2010-07-29 Jody Firmin Voorspoels Combination formulations
AR069539A1 (es) 2007-07-25 2010-02-03 Tibotec Pharm Ltd Avances respecto de las formulaciones de comprimidos contra el vih
NZ584998A (en) 2007-11-20 2012-08-31 Janssen Pharmaceutica Nv Cycloalkyloxy-and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor
GT200800303A (es) * 2007-12-24 2009-09-18 Combinacion anti-retroviral
EA201591353A1 (ru) * 2008-05-02 2016-01-29 Джилид Сайэнс, Инк. Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
PE20110994A1 (es) * 2009-02-06 2012-01-24 Gilead Sciences Inc Comprimidos antivirales que comprenden elvitegravir, emtricitabina, disoproxil fumarato de tenofovir y un derivado de tiazol
CA2776807C (en) * 2009-09-17 2018-10-16 Mylan Laboratories Limited An improved process for the preparation of darunavir
WO2011141921A1 (en) 2010-05-10 2011-11-17 Hetero Research Foundation Darunavir compositions
HUE035241T2 (en) 2011-07-07 2018-05-02 Janssen Sciences Ireland Uc Darunavir combination products
BR112014000195A2 (pt) 2011-07-07 2017-02-21 Janssen R&D Ireland formulações de darunavir
WO2013115916A1 (en) 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
JP2018502118A (ja) 2015-01-03 2018-01-25 マイラン・ラボラトリーズ・リミテッドＭｙｌａｎ Ｌａｂｏｒａｔｏｒｉｅｓ Ｌｉｍｉｔｅｄ 非晶質ヘミフマル酸テノホビルアラフェナミドおよびその予備混合物を調製するプロセス

Also Published As

Publication number Publication date
EA201490222A1 (ru) 2014-04-30
CN103826616B (zh) 2016-08-10
WO2013004818A1 (en) 2013-01-10
PT2729130T (pt) 2017-12-13
US20230302024A1 (en) 2023-09-28
AU2012280198A1 (en) 2014-01-09
KR102058097B1 (ko) 2019-12-20
MX343689B (es) 2016-11-16
CY1121999T1 (el) 2020-07-31
AU2012280198B2 (en) 2016-12-22
BR112014000290B1 (pt) 2022-05-10
CA2838659A1 (en) 2013-01-10
NO2729130T3 (pt) 2018-02-03
KR20140068845A (ko) 2014-06-09
US11654150B2 (en) 2023-05-23
RS56667B1 (sr) 2018-03-30
EP2729130B1 (en) 2017-09-06
PL2729130T3 (pl) 2018-02-28
SI2729130T1 (en) 2018-03-30
JP2014520787A (ja) 2014-08-25
CA2838659C (en) 2020-02-18
HUE035241T2 (en) 2018-05-02
JP6122427B2 (ja) 2017-04-26
ES2651212T3 (es) 2018-01-25
AU2012280198A8 (en) 2014-01-16
IL229933A (en) 2017-09-28
EA026587B1 (ru) 2017-04-28
CN103826616A (zh) 2014-05-28
HRP20171889T1 (hr) 2018-01-12
EP2729130A1 (en) 2014-05-14
US20200093840A1 (en) 2020-03-26
US20140142070A1 (en) 2014-05-22
MX2013015199A (es) 2014-09-01
DK2729130T3 (en) 2017-12-11
LT2729130T (lt) 2018-01-10

Similar Documents

Publication Publication Date Title
BR112014000290A2 (pt) formulações de combinação de darunavir
BR112014000195A2 (pt) formulações de darunavir
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
BR112015020453A8 (pt) "formas de dosagem de liberação prolongada orais de tofacitinibe e uso de tofacitinibe
DOP2016000298A (es) Pirazolopiridinas y pirazolopirimidinas
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
BR112014019171A8 (pt) Composições intranasais de dexdetomida e seus métodos de uso
CL2014001585A1 (es) Compuestos derivados de betulina; composicion farmaceutica; y el uso de los mismos en el tratamiento y prevencion de una infeccion por vih.
BR112015007586A2 (pt) derivados de pirrolo[3,2-d]pirimidina para o tratamento de infecções virais e outras doenças
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
PA8809601A1 (es) Combinación anti-retroviral
BR112014009866A2 (pt) formulações de anticorpos e métodos
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
BRPI1013988A2 (pt) composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
BR112013015877A2 (pt) composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
ES2524385R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
UY35209A (es) Compuestos tricíclicos

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: GILEAD SCIENCES, INC. (US) , JANSSEN SCIENCES IREL

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/07/2012, OBSERVADAS AS CONDICOES LEGAIS